top of page

- 3 days ago

Vor Bio is trying to help AML patients who receive a stem cell transplant to be more amenable to follow-on therapies - they just had key PoC data

President and CEO Robert Ang describes how Vor knocks out CD33 in transplant cells before they are administered so that patients can tolerate follow-on treatments like Mylotarg and CAR-T easier and earlier. He describes clinical data the company announced last month.

Recent Posts

Oxford, UK based Enara Bio announced a $32.5M series B to further its work developing TCR based therapies that target antigens found in the 'dark genome'

Flagship's ProFound Therapeutics is searching for proteins for use as therapeutics and targets beyond those found in the traditional protein coding regions of DNA

Mathai Mammen provides an update on the latest at FogPharma, and his philosophy of following the cadence of science, not the calendar

Comentarios

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

bottom of page